Elai Davicioni

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• ERG orchestrates a dedifferentiation–senescence–inflammation triad in prostate cancer

  Molecular Cancer Research · 2026-06-22

• Supplementary Figure S4 from ATAD2 Drives Prostate Cancer Progression to Metastasis

  2026-06-17

• Supplementary Figure S5 from ATAD2 Drives Prostate Cancer Progression to Metastasis

  2026-06-17

• Supplementary Figure S1 from ATAD2 Drives Prostate Cancer Progression to Metastasis

  2026-06-17

• Supplementary Figure S3 from ATAD2 Drives Prostate Cancer Progression to Metastasis

  2026-06-17

• Supplementary Figure S2 from ATAD2 Drives Prostate Cancer Progression to Metastasis

  2026-06-17

• Figure S3 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Figure S1 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Figure S2 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Supplementary Data Table S3 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Figure S4 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Supplementary Table S2 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Supplementary Table S1 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Data from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Supplementary Data Table S4 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer: Final results and biomarker analyses of the SURE-01 trial.

  Journal of Clinical Oncology · 2026-05-27

• Characterizing the Activity of Inflammasome‐Related Genes and Their Association With Oncological Outcomes in Prostate Cancer

  The Prostate · 2026-05-26

• IP62-05 CORRELATIVE ANALYSIS OF THE EXPRESSION OF TWO PET IMAGING TARGETS, PSMA AND ACP3, IN LARGE RP COHORT FROM THE DECIPHER GRID REGISTRY

  The Journal of Urology · 2026-04-27

• The role of HAI-1 in urothelial bladder cancer: Tissue expression, ectodomain shedding and clinical outcomes

  Biochemistry and Biophysics Reports · 2026-04-24

• Understanding randomized controlled trial generalizability through an embedded molecular diagnostics trial

  JNCI Cancer Spectrum · 2026-04-12